Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:57 AM
Ignite Modification Date:
2025-12-25 @ 4:57 AM
NCT ID:
NCT02391818
Eligibility Criteria:
Inclusion Criteria:
1. Women with breast cancer (stage 0-III)
2. Scheduled to receive any of the following individual treatment protocols:
1. ACT
2. Radiation only
Exclusion Criteria:
1. Required assistive device for ambulation in the 6 months prior to starting treatment
2. Previous taxane or platinum chemotherapy (paclitaxel/Taxol®, docetaxel/Taxotere®, cabazitaxel/Jevtana®, cisplatin, carboplatin, and oxaliplatin)
3. Inability to stand or walk without assistance
4. BMI \>40 (see chart below)
5. Pre-existing vestibular, visual, somatosensory, orthopedic, and neurologic disease before entering the study including but not limited to being legally blind (ICD9 368.3, 369.0-369.2 lower extremity amputation (ICD9 895.0-897.7), and Diabetes (ICD9 249.0-250.93, 257.2)
6. Evidence of central nervous system metastasis
7. Cognitive difficulties or medical conditions that, in the opinion of the study investigators, will affect testing protocols
8. Enrollment in other trial aimed at treating CIPN.
Healthy Volunteers:
False
Sex:
FEMALE
Study:
NCT02391818
Study Brief:
Protocol Section:
NCT02391818